Locations:
SearchAdvertisement
Consider each patient's unique disease progression and treatment goals when choosing a strategy
Findings also indicate reduced risk of serious liver events
TRANSITION-T2D RCT results for patients with T2D receiving MDI
Provider vigilance and patient education are key for management
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Screening and medication key to better outcomes
Cleveland Clinic’s Endocrinology & Metabolism Institute is working to offer novel opportunities and therapies for diabetes and kidney disease
Two major trials promise key progress against the last unaddressed major risk factor
Genetic variants may help identify which patients could benefit which patients from more aggressive glycemia treatment
Medications for patients with diabetes and cardiovascular disease
Predictive tool should help in treatment decisions
Advertisement
Advertisement